Efficacy and Toxicity of Gemcitabine and Pegylated Liposomal Doxorubicin in Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer

Karaoglu A., Arslan U. Y. , ÖZKAN M., KALENDER M. E. , Alici S., Coskun U., ...More

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.10, no.1, pp.63-66, 2009 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 10 Issue: 1
  • Publication Date: 2009
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.63-66
  • Gazi University Affiliated: Yes


Background: Treatment of patients with platinum resistant/refractory ovarian cancer is a significant problem. In this study, we evaluated the efficacy and tolerability of the combination of gemcitabine and pegylated liposomal doxorubicin (PLD) in patients with platinum resistant/refractory ovarian cancer. Patients and Methods: We retrospectively evaluated the activity and toxicity of gemcitabine and PLD combination in 35 patients with recurrent platinum resistant/refractory ovarian cancer who had been treated and followed up in 7 centers in Turkey between December 2005 and June 2008. The patients received gemcitabine 1.000 mg/m(2) on day 1 and 8, and PLD 25 mg/m(2) on day 1 every 28 days. Results: A total of 187 cycles (median, 6 cycles) were delivered. An objective response rate of 28,6% (1 complete, 9 partial response) was achieved. Additionally, 16 patients (45.7%) had disease stabilization. The median time-to-progression was 6 months (95% confidence interval, 4-8) and the median overall survival was 17 months (95% confidence interval, 12-22). Grade 3-4 hematologic toxicities were as follows: leucopenia (14.3%), neutropenia (8.6%), and anemia (2.9%). One febrile neutropenic episode (2.9%) was observed. Non-hematologic toxicity was well tolerated and easily managed and no grade 3-4 palmoplantar erytrodysestesia (PPE) was observed. Conclusion: The combination of gemcitabine and PLD is an effective and tolerable treatment option, with 74.3% disease control rate for patients with platinum resistant/refractory ovarian cancer.